Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Peanut and Nut Allergy Clear all
Completed Phase 1Phase 2 Interventional Results available

Walnut Oral Immunotherapy for Tree Nut Allergy

NCT01546753
View directory record Official record
Conditions
Tree Nut Allergy
Interventions
Walnut Protein Powder, Oat Powder (placebo), Open-label Walnut Protein Powder
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
6 Years to 45 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 11, 2023 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

The Peanut Oral Immunotherapy Study: Safety, Efficacy and Discovery

NCT02103270
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut Protein 4,000mg, Oat Flour, Peanut Protein 300 mg
Drug
Lead sponsor
Stanford University
Other
Eligibility
7 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2019 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 3 Interventional

Safety Study of Viaskin Peanut to Treat Peanut Allergy

NCT02916446
View directory record Official record
Conditions
Peanut Allergy
Interventions
Viaskin Peanut 250 mcg, Placebo
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
4 Years to 11 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
26
States / cities
Little Rock, Arkansas • Mission Viejo, California • Rolling Hills Estates, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Early Phase 1 Interventional

Oral Peanut Immunotherapy for Peanut Allergic Patients

NCT01891136
View directory record Official record
Conditions
Peanut Hypersensitivity
Interventions
Peanut protein
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
1 Year to 16 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Jul 23, 2026, 4:15 PM EDT
Recruiting Phase 1 Interventional

Safety of MOON101 for the Treatment of Peanut Allergy

NCT07580898
View directory record Official record
Conditions
Peanut Allergy
Interventions
Dose A, Dose B, Dose C, Dose D, Dose E, Placebo
Combination Product
Lead sponsor
Moonlight Therapeutics, Inc.
Industry
Eligibility
4 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
5
States / cities
Little Rock, Arkansas • Atlanta, Georgia • Overland Park, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Peanut Allergy Vaccine Study in Healthy and Peanut-allergic Adults

NCT00850668
View directory record Official record
Conditions
Food Hypersensitivity, Hypersensitivity, Immediate Hypersensitivity, Peanut Hypersensitivity
Interventions
E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3
Biological
Lead sponsor
Allertein Therapeutics, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 1 Interventional

HAL-MPE1 Safety and Tolerability Study

NCT02991885
View directory record Official record
Conditions
Peanut Allergy
Interventions
HAL-MPE1, HAL-MPE1 placebo
Biological · Drug
Lead sponsor
HAL Allergy
Industry
Eligibility
5 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
6
States / cities
Baltimore, Maryland • New York, New York • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT

NCT01987817
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101 powder provided in capsules, Placebo powder provided in capsules
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 26 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
8
States / cities
Little Rock, Arkansas • San Diego, California • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2021 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Not applicable Interventional Results available

Oral Peanut Immunotherapy

NCT01324401
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut flour OIT
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 21 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Jul 23, 2026, 4:15 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of ENP-501 in Peanut-Allergic and Non-Allergic Participants

NCT07117669
View directory record Official record
Conditions
Peanut Allergy
Interventions
ENP-501, Placebo
Drug
Lead sponsor
N-Fold, LLC
Industry
Eligibility
14 Years to 50 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age

NCT03211247
View directory record Official record
Conditions
Peanut Allergy
Interventions
Part A Viaskin Peanut 250 mcg, Part A Viaskin Peanut 100 mcg, Part A Placebo, Part B Viaskin Peanut 250 mcg, Part B Placebo
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
1 Year to 3 Years
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
27
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2024 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts

NCT05432388
View directory record Official record
Conditions
Allergy, Peanut
Interventions
LOU064, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 23, 2026, 4:15 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects

NCT05476497
View directory record Official record
Conditions
Peanut Allergy
Interventions
VLP Peanut, Placebo
Biological
Lead sponsor
Allergy Therapeutics
Industry
Eligibility
18 Years to 50 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
10
States / cities
Tucson, Arizona • Tampa, Florida • Kansas City, Kansas + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Tolerance Following Peanut Oral Immunotherapy

NCT01750879
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut Flour, Oat Flour
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Xolair Enhances Oral Desensitization in Peanut Allergic Patients

NCT01290913
View directory record Official record
Conditions
Peanut Allergy
Interventions
Omalizumab
Drug
Lead sponsor
Lynda Schneider
Other
Eligibility
7 Years to 25 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Jul 23, 2026, 4:15 PM EDT
Recruiting Phase 2 Interventional

Efficacy of Tezepelumab in Peanut Oral Immunotherapy

NCT07015996
View directory record Official record
Conditions
Peanut Allergy
Interventions
Tezepelumab, Peanut Oral Immunotherapy (OIT), Placebo for Tezepelumab
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
10
States / cities
Little Rock, Arkansas • Los Angeles, California • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Oral Desensitization to Peanut in Peanut Allergic Children and Adults Using CPNA Peanut OIT Safety Follow-On Study

NCT02198664
View directory record Official record
Conditions
Peanut Allergy
Interventions
AR101 - Peanut protein capsule
Biological
Lead sponsor
Aimmune Therapeutics, Inc.
Industry
Eligibility
4 Years to 26 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
Little Rock, Arkansas • San Diego, California • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Jul 23, 2026, 4:15 PM EDT
Terminated Phase 1 Interventional

Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-201 in Subjects Ages 16-35 With Peanut Allergy

NCT04950504
View directory record Official record
Conditions
Peanut Allergy
Interventions
CNP-201, Placebo
Drug
Lead sponsor
COUR Pharmaceutical Development Company, Inc.
Industry
Eligibility
16 Years to 55 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Scottsdale, Arizona • Mountain View, California • Rolling Hills Estates, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2023 · Synced Jul 23, 2026, 4:15 PM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

The Safety and Efficacy of a Peanut Immunotherapy Dissolving Film for Peanut Allergy

NCT01897077
View directory record Official record
Conditions
Peanut Allergy
Interventions
Peanut Dissolving Film
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2018 · Synced Jul 23, 2026, 4:15 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Expecting Mother's Study of Consumption or Avoidance of Peanut and Egg

NCT06260956
View directory record Official record
Conditions
Allergy and Immunology, Peanut and Nut Allergy, Egg Allergy, Food Allergy in Infants, Food Allergy Peanut
Interventions
Consumption, Avoidance
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
1 Day and older · Female only
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Intervention to Reduce Early (Peanut) Allergy in Children

NCT04604431
View directory record Official record
Conditions
Food Allergy Peanut, Food Allergy in Infants
Interventions
iREACH CDS Tool
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
4 Months and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
30
States / cities
Arlington Heights, Illinois • Bloomington, Illinois • Chicago, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy

NCT05138757
View directory record Official record
Conditions
Peanut Allergy
Interventions
Prebiotic, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
4 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Chicago, Illinois • Hyde Park, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Jul 23, 2026, 4:15 PM EDT
Completed Phase 2 Interventional Results available

Peanut Oral Immunotherapy in Children

NCT01867671
View directory record Official record
Conditions
Peanut Hypersensitivity
Interventions
Peanut Oral Immunotherapy - Liquid Extract, Placebo for Peanut Oral Immunotherapy - Liquid Extract form, Peanut Oral Immunotherapy - Peanut Flour, Placebo for Peanut Oral Immunotherapy - Peanut Flour
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Months to 48 Months
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
5
States / cities
Little Rock, Arkansas • Stanford, California • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2020 · Synced Jul 23, 2026, 4:15 PM EDT
Recruiting Phase 2 Interventional

Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients

NCT05695261
View directory record Official record
Conditions
Allergy, Peanut, Peanut Allergy, Peanut Hypersensitivity, Peanut-Induced Anaphylaxis, Food Allergy, Food Allergy Peanut
Interventions
Microbial Transplantation Therapy, Antibiotic, Placebo (in place of MTT), Placebo (in place of antibiotics), Oral Immunotherapy (OIT)
Biological · Drug · Other
Lead sponsor
Rima Rachid
Other
Eligibility
12 Years to 17 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 23, 2025 · Synced Jul 23, 2026, 4:15 PM EDT